StockData
Royalty Pharma plc logo

Royalty Pharma plc (RPRX) stock

RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3050% above fair value
$68.67−0.01 (-0.01%)

Close on Nov 18, 2026Market cap $39.49BP/E 39.0Yield –

Royalty Pharma operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Royalty Pharma's operating income for the twelve months ending Jun 30, 2026 was $1.51B, down 17.9% year over year. For fiscal 2025 it was $1.56B, up 20.7% from the year before. The highest annual figure on record is $2.62B in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.56B+20.7%
FY2024Dec 31, 2024$1.29B-13.4%
FY2023Dec 31, 2023$1.49B+385.9%
FY2022Dec 31, 2022$307.07M-78.5%
FY2021Dec 31, 2021$1.43B-10.3%
FY2020Dec 31, 2020$1.60B-39.2%
FY2019Dec 31, 2019$2.62B+92.3%
FY2018Dec 31, 2018$1.36B–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$133.12M-36.5%
Q1 FY2026Mar 31, 2026$563.04M+5.4%
Q4 FY2025Dec 31, 2025$388.38M+7.4%
Q3 FY2025Sep 30, 2025$427.16M-41.9%
Q2 FY2025Jun 30, 2025$209.80M-22.2%
Q1 FY2025Mar 31, 2025$534.18M–
Q4 FY2024Dec 31, 2024$361.51M-41.0%
Q3 FY2024Sep 30, 2024$735.07M+385.4%
Q2 FY2024Jun 30, 2024$269.63M+8.4%
Q1 FY2024Mar 31, 2024-$73.77M-115.4%
Q4 FY2023Dec 31, 2023$612.90M–
Q3 FY2023Sep 30, 2023$151.44M-21.2%
Q2 FY2023Jun 30, 2023$248.84M-34.1%
Q1 FY2023Mar 31, 2023$478.97M+118.0%
Q4 FY2022Dec 31, 2022-$482.66M-414.6%
Q3 FY2022Sep 30, 2022$192.21M-36.6%
Q2 FY2022Jun 30, 2022$377.79M-49.3%
Q1 FY2022Mar 31, 2022$219.72M-4.2%
Q4 FY2021Dec 31, 2021$153.42M-51.1%
Q3 FY2021Sep 30, 2021$303.05M-40.6%
Q2 FY2021Jun 30, 2021$744.95M+82.0%
Q1 FY2021Mar 31, 2021$229.30M-36.6%
Q4 FY2020Dec 31, 2020$314.06M-76.4%
Q3 FY2020Sep 30, 2020$510.57M-4.1%
Q2 FY2020Jun 30, 2020$409.35M+24.9%
Q1 FY2020Mar 31, 2020$361.43M–
Q4 FY2019Dec 31, 2019$1.33B–
Q3 FY2019Sep 30, 2019$532.50M–
Q2 FY2019Jun 30, 2019$327.86M–

More Royalty Pharma figures

See a number that looks wrong?